Half Yearly Report and Accounts
Released
Released
Announcement PDF
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Half Year Report
For the six months ended 30 June 2023
Doctor Care Anywhere Group PLC
Company number: 08915336
ARBN: 645 163 873
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Contents
Appendix 4D – Half Year Report
2
Directors’ Report
6
Unaudited Interim Condensed Consolidated Financial Statements
11
Notes to the Interim Condensed Consolidated Financial Statements
16
Directors’ Declaration
30
Independent Review Report to Doctor Care Anywhere Group PLC
31
Corporate Directory
33
Page | 1
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Appendix 4D – Half Year Report
Reporting Period
Current reporting period (“1H23”): 1 January 2023 to 30 June 2023
Previous corresponding period (“1H22”): 1 January 2022 to 30 June 2022
Basis of Preparation
This Appendix 4D has been prepared in accordance with measurement and
recognition (but not disclosure) requirements of International Financial Reporting
Standards in conformity with the requirements of the Companies Act 2006 (UK).
The interim results for the 6 months ended 30 June 2023 and the comparatives for
30 June 2022 are unaudited but have been reviewed by the Company’s
independent auditor. A copy of the review report is included at the end of this
report.
Note all values in the Appendix 4D and Directors’ Report are subject to rounding
differences.
Results for Announcement to the Market
1H23
1H22
Change
%
Revenue
£m's
19.2
15.2
4.0
26.4%
Net loss
£m's
(6.2)
(11.6)
5.5
47.0%
Net tangible assets per security
£'s
(0.00)
0.03
(0.03)
(102.9%)
Revenue
Revenue grew by 26.4% in 1H23 compared with 1H22, driven both by an increased
volume of consultations delivered to the Company’s growing base of Activated
Lives and by an increase in the average price per consultation.
Page | 2
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Net Loss
A summary of net loss adjusted for one-off charges is as follows:
1H23
1H22
Change
%
£m's
(6.2)
(11.6)
5.5
47.0%
Restructuring costs
£m's
-
1.6
GP2U impairment charge
Underlying net loss
£m's
£m's
1.7
(4.5)
(10.0)
5.6
55.5%
Net loss
Add back
Net loss for 1H23 includes an impairment charge of £1.7m against the carrying value
of GP2U. Excluding this charge, underlying net loss for 1H23 was £4.5m.
Net loss for 1H22 includes one-off restructuring costs of £1.6 million. These costs
represented redundancy and notice payments for employees departing the
organisation. Adjusting for this, net underlying loss for 1H22 was £10.0 million.
Taking into account these adjustments, net underlying loss for 1H23 reduced by
56%, or £5.6m, compared with 1H22. This is through ongoing growth in the
business and a focus on productivity improvements and margin expansion as the
business drives towards profitability in 2024.
Net Tangible Assets Per Security
Net tangible assets decreased by £12.4 million from £12.1 million at 30 June 2022 to
a net tangible liability of £0.3m million at 30 June 2023 (down 103%). This was driven
by a combined net loss of £16.6m in 2H22 and 1H23 within which £4.2m related to
impairment of intangible assets.
As a result of this, net tangible assets per security decreased from £0.03 at 1H22 end
to £0.00 at 1H23 end.
Dividends
No dividends have been declared, nor were any paid in the prior period.
Joint Ventures
The Company is party to a joint venture with AXA PPP Healthcare Group Limited
(“AXA Health”). The Company and AXA Health each hold 50% of the issued share
capital of Doctor at Hand Diagnostics Limited.
Page | 3
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Going Concern
These financial statements have been prepared on a going concern basis, which
assumes that the Group and the Company will continue to be able to meet their
liabilities as they fall due for the foreseeable future, which has been taken as 12
months from the date of approval of the Half Year Report.
The Directors have considered detailed cash flow forecasts to determine the
appropriateness of preparing these financial statements on a going concern basis.
On 12 December 2022, the Company announced that it had entered into a fouryear secured and guaranteed loan agreement with AXA Health to borrow up to
£10.0m in 3 tranches (“Loan”). The Loan is to be used by the Company for general
working capital purposes. At the date of this report, all three tranches have been
drawn down. Under the terms and covenants of the loan, the Group is required to
maintain a minimum cash balance; in August 2023 the Company agreed with AXA
Health a reduction in the minimum from £3.0m to £1.5m in light of the Company’s
progress since December 2022. The minimum cash balance requirement will be
subject to a further review in September 2024. Therefore, to prepare the accounts
on a Going Concern basis, this minimum cash balance requirement must be met
throughout the Going Concern period.
The forecast is dependent on a number of key assumptions and dependencies,
the most material of which are as follows:
Minimum growth of 30% in demand for consultations from the Company’s
patient base
The ability to recruit and retain enough clinicians to meet patient demand
The ability to drive productivity gains which underpin the Company’s 2023
plan together with no material unanticipated increases in non-operating
costs
Management has assessed all the above assumptions to be reasonable based on
its expectations of the business going forward. As part of this going concern
assessment, four scenarios were considered for the Group, being a management
case and three other scenarios using a set of plausible downside assumptions to
that management case. The management case is built up from detailed
projections and the aforementioned assumptions. The downside scenarios
considered were as follows:
AXA Health consultations being 10% below the management case.
The percentage of consultations treated by Advanced Nurse Practitioners
(“ANPs”) being 10ppt below the management case.
The switch from a primarily locum based ANP staff base, to an employed
ANP staff base taking four months longer than the management case.
In all three downside scenarios and for all three scenarios combined, the Group
had adequate resources to continue in operational existence for the going concern
period.
Page | 4
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
In order for the Company to breach the terms of the AXA loan facility and therefore
not to remain a Going Concern, the following combination of scenarios would be
required:
Consultation volumes to fall by 13.9% below the management case; and
The percentage of consultations treated by ANPs being 10ppt below the
management case; and
The switch from a primarily locum based ANP staff base, to an employed
ANP staff base taking four months longer than the management case.
Management considers the possibility of the above scenarios occurring
concurrently to be low:
•
•
•
July AXA volumes were largely in line with the management case, giving
assurance over trading volumes.
ANPs can treat a higher proportion of patient cases than included the
management model.
Management has a plan in place to increase the proportion of employed
ANPs in its workforce.
In addition, the Directors consider that the Group is well positioned to manage its
business risks and have had regard to a number of factors including current
trading performance, the outcomes of comprehensive forecasting, and a range of
possible future trading impacts. The Directors are of the view that there is a
reasonable expectation that the Group has adequate resources to continue in
operational existence for the next 12 months following the date of approval of the
financial statements. For this reason, they continue to adopt a going concern basis
in the preparation of these financial statements.
Page | 5
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Directors’ Report
The Directors present the condensed consolidated interim financial report of
Doctor Care Anywhere Group PLC (“the Company” or “Doctor Care Anywhere”) and
its subsidiaries (“the Group”) for the six months ended 30 June 2023 (“1H23”).
Directors
The Directors in office during the reporting period and as at the date of this report
are shown below:
Romana Abdin
Independent Non-Executive Director
David Ravech
Non-Executive Director
John Stier
Independent Non-Executive Director,
Independent Chairman from 28 March 2023
Dr Aleksandra Spencer
Independent Non-Executive Director
(appointed 3 July 2023)
Richard Dammery
Independent Chairman
(resigned 28 March 2023)
Vanessa Wallace
Independent Non-Executive Director
(resigned 28 March 2023)
Simon Calver
Non-Executive Director
(resigned 28 March 2023)
About Doctor Care Anywhere
Doctor Care Anywhere Group PLC is the UK’s largest private provider of telehealth
services. The Company works with insurers, healthcare providers and corporate
customers to connect patients to a range of digitally-enabled telehealth services
on its proprietary platform. It is committed to delivering the best possible patient
experience and clinical care through digitally enabled, joined up, evidence-based
pathways.
Page | 6
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Operating and Financial Review
000's
1H23
1H22
Eligible Lives
2,837
2,526
Activated Lives
966
756
Consultations
377
303
Repeat Patients
265
First-Time Patients
111
Secondary-Care Journeys
20
Change
%
2H22
Change
%
311
12.3%
2,720
117
4.3%
210
27.8%
869
97
11.2%
74
24.4%
311
66
21.2%
206
59
28.6%
222
43
19.4%
97
14
14.4%
88
23
26.1%
14
6
45.7%
17
3
20.0%
Growth continued across all key operational metrics in 1H23. At the end of 1H23,
Activated Lives were 966,000, up 28% on the prior comparative period (“pcp”). The
Company added 97,000 Activated Lives in 1H23, slightly fewer than the 113,000
Activated Lives added in 2H22, primarily due to constraints in growing clinician
capacity. The launch of Mixed Clinical Workforce (“MCW”) in mid-June 2023 has
significantly improved the Company’s ability to source clinician capacity.
Consultation volumes grew to 377,000 in 1H23, up 24% on the pcp. Patient demand
remains strong and continues to grow, as evidenced by the increases in both
repeat patients and first-time patients, but consultation volume growth was also
constrained by clinician capacity, with the Company experiencing very high
utilisation of available consultations.
Following the launch of MCW in mid-June 2023, the Company expects clinician
availability to improve. MCW refers to the addition of Advanced Nurse Practitioners
(“ANPs”) to the Company’s clinical workforce. ANPs are educated to Masters level
in clinical practice and have been assessed as competent in practice. They have
the authority to make autonomous decisions in the assessment, diagnosis and
treatment of patients.
MCW went live in mid-June and over 20,000 appointments were provided by ANPs
in June and July, showing a strong uptake for the service. The launch of MCW has
materially improved clinician supply with the Company already having around 80
ANPs to serve patients. MCW will also reduce DCA’s cost to serve, key to driving
margins and the Company becoming profitable in 2024.
The Company made progress with its secondary care proposition, which integrates
primary and secondary care through the provision of GP consultations, diagnostic
tests and review of such tests by specialist consultants. In 1H23, 20,000 patients
completed this pathway, up 20% on 2H22. Growth and profitability in this area
continues to underperform expectations, however, with work underway to
improve this.
In addition to the above, in July 2023 the Company completed the sale of its
Australian subsidiary GP2U to My Emergency Doctor (MED) for A$3.0m, of which
A$0.5m was paid in cash, and the balance paid in shares in MED. The sale of GP2U
enables the business to focus on its core UK market while reducing ongoing losses
by £0.5m pa.
Page | 7
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Finally, the Company has now fully drawn down on its £10.0m loan facility with AXA
Health, following drawdown of tranche 3 of the loan in early July; and has agreed
the reduction in minimum cash covenant described earlier. These steps,
combined with ongoing growth, the efficiency gains achieved from the launch of
MCW and the sale of GP2U, are expected to see the Company through to
breakeven in Q1 2024.
Financial KPIs
Consolidated income statement
£m's
1H23
1H22
Change
%
2H22
Change
%
Revenue
19.2
15.2
4.0
26.4%
14.2
5.0
35.3%
Cost of sales
(10.8)
(8.8)
(2.0)
(22.6%)
(8.1)
(2.7)
(32.7%)
8.3
43.6%
6.3
41.8%
2.0
1.7 ppt
31.7%
6.0
42.5%
2.3
1.1 ppt
38.8%
(3.6)
(3.2)
(0.4)
(13.1%)
(3.2)
(0.4)
(14.1%)
4.7
24.6%
3.1
20.6%
1.6
4 ppt
50.8%
2.8
19.9%
1.9
4.6 ppt
66.8%
(8.3)
0.0
(13.9)
0.2
5.7
(0.1)
40.6%
(82.9%)
(8.2)
(0.3)
(0.1)
0.3
(1.1%)
109.9%
(3.5)
(18.5%)
(10.7)
(63.1%)
7.1
44.7 ppt
66.8%
(5.6)
(39.8%)
2.1
21.3 ppt
37.2%
(1.1)
(0.8)
(0.3)
(38.2%)
(1.1)
(0.1)
(4.9%)
EBIT
(4.6)
(11.5)
6.8
59.5%
(6.7)
2.0
30.5%
Finance income/(expense)
(0.2)
(0.0)
(0.2)
n/m
(0.0)
(0.2)
(413.2%)
Loss before tax
(4.8)
(11.5)
6.6
57.8%
(6.7)
1.9
28.0%
Tax
0.6
0.1
0.4
395.6%
0.1
0.4
291.6%
Loss after tax
(4.3)
(11.4)
7.1
62.3%
(6.6)
2.3
35.0%
Results from discontinued operations
(1.9)
(0.3)
(1.6)
(601.1%)
(2.8)
0.9
33.0%
Net loss
(6.2)
(11.6)
5.5
47.1%
(9.4)
3.2
34.4%
Net Operating Cash Flows
(4.4)
(8.6)
4.2
48.6%
(6.0)
1.6
26.5%
Gross Profit
Gross Profit Margin
Operating costs
Contribution
Contribution Margin
Non-operating costs
Share of JV profit/(loss)
EBITDA
EBITDA Margin
Depreciation and amortisation
Commentary
Revenue in 1H23 was £19.2 million, up 35.3% on 2H22 and 26.4% on 1H22. Revenue
growth was driven by an increase in the volume of consultations delivered to
patients together with a contractual inflationary increase in our price per
consultation.
Page | 8
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Gross profit in 1H23 was £8.3 million, up 38.8% on 2H22 and 31.7% on 1H22. Gross
margins continued to improve from 41.8% in 1H22, to 42.5% in 2H22 and up to 43.6%
in 1H23. The increase from 2H22 to 1H23 is primarily driven by the increased price
received from AXA Health, with a small benefit seen from the launch of MCW in
mid-June 23.
Contribution in 1H23 was £4.7 million, up 66.8% on 2H22 and 50.8% on 1H22.
Contribution margin of 24.6% was 4.0ppt higher than 1H22 and 4.6ppt higher than
2H22. The 2H22 improvement was driven by a 6% reduction in the average
operating cost per consultation resulting from a range of efficiency gains.
EBITDA loss in 1H23 was £3.5 million, a decrease of 37.2% on 2H22 and 66.8% on
1H22. This is driven by the above improvements to gross profit and contribution,
together with reductions in non-operating costs. The table below shows the
underlying movement in non-operating costs, after excluding one off items:
£m's
1H23
1H22
Change
%
2H22
Change
%
Sales and marketing costs
Technology costs
0.4
1.5
1.3
4.3
(0.9)
(2.8)
(69.1%)
(65.0%)
0.5
3.1
(0.1)
(1.6)
(17.6%)
(52.0%)
6.1%
General and administration costs
6.7
8.4
(1.8)
(21.2%)
6.3
0.4
Other operating income
(0.3)
(0.3)
-
-
(0.3)
-
-
Share based payments
Total non-operating costs
0.0
8.3
0.2
13.9
(0.2) (95.0%)
(5.7) (40.6%)
(1.4)
8.2
1.4
0.1
100.7%
1.1%
Less share based payments
(0.0)
(0.2)
-
(1.6)
8.3
12.1
(1.3)
(13.8%)
Less restructuring costs
Underlying non-operating costs
1.4
(3.9)
(31.9%)
9.6
Adjusting for exceptional costs, underlying non-operating costs were £8.3m, a
13.8% reduction on 2H22 and 31.9% reduction on 1H22. The reduction from 1H22 to
1H23 was driven primarily by the one-off restructuring exercise in 1H22 which
reduced ongoing salary costs across all departments. The reduction from 2H22 to
1H23 is primarily driven by the £1.6m reduction in technology costs. £1.1m of this
reduction was driven by an increase in the quantity of costs capitalised in the
period (£1.6m in 1H23 vs. £0.5m in 2H22), with the balance of £0.5m being a
reduction in overall spend in the department driven by efficiency gains.
Page | 9
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Operating Cash flow
Operating cash flow trend largely followed EBITDA trend in the period when
adjusted for non-cash items:
£m's
1H23
1H22
Change
%
2H22
Change
%
EBITDA
Add back share based payments
Add back restructuring costs
Underlying EBITDA
(3.5)
0.0
(3.5)
(10.7)
0.2
1.6
(8.9)
7.1
66.8%
2.1
1.1%
5.3
60.2%
(5.6)
(1.4)
(7.0)
3.5
49.8%
Net Operating Cash Flows
Add back GP2U cash flows
Add back restructuring costs
Underlying net operating cash flows
(4.5)
0.1
(4.4)
(9.1)
0.5
1.5
(7.1)
4.5
50.1%
1.5
24.4%
2.7
37.7%
1.3
22.9%
(6.0)
0.2
0.1
(5.7)
Net operating cash outflows in 1H23 were £4.5 million, a 24.4% reduction on 2H22
and a 50.1% reduction on 1H22. The reduction in operating cash outflows in 1H22
included £1.5 million of payments in respect of restructuring costs and GP2U
related costs. Excluding the impact of these items, operating cash outflows in 1H23
decreased 22.9% on 2H22 and 37.7% on 1H22.
The reduction against both periods was mostly driven by the same factors driving
the improvements in EBITDA. The variances between EBITDA and net operating
cash flows are primarily driven by working capital movements related to timing of
invoice payments and revenue receipts, which are often lumpy in nature and do
not correspond exactly with revenue and cost in the related period.
Page | 10
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Unaudited Interim Condensed Financial Statements
Prepared under International Accounting Standard 34 for the six month period
ended 30 June 2023
Interim Condensed Statement of Comprehensive Income
For the six months ended 30 June 2023
Note
30 June
2023
Unaudited
£’000
19,154
30 June
2022
Unaudited
£’000
15,154
Cost of sales
(10,810)
(8,817)
Gross profit
8,344
6,337
Revenue
3
Administrative expenses
6
(13,321)
(18,259)
Other operating income
7
307
321
Operating loss
8
(4,670)
(11,601)
Share of profit/(loss) of joint venture
14
27
158
7
1
(202)
(14)
(4,838)
(11,456)
560
113
(4,278)
(11,343)
(1,872)
(267)
(6,150)
(11,610)
£
£
Finance income
Finance costs
9
Loss before taxation
Tax credit
10
Loss for the financial period from
continuing operations
Loss on discontinued operations, net of tax
5
Total comprehensive loss for the period
Loss per share
Basic and diluted EPS
11
(0.02)
(0.03)
Basic and diluted EPS – continuing
operations
11
(0.01)
(0.03)
The notes on pages 16 to 29 form part of these interim condensed consolidated
financial statements.
Page | 11
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Interim Condensed Consolidated Statement of Financial
Position
Note
30 June
2023
Unaudited
£’000
31 December
2022
Audited
£’000
Property, plant and equipment
12
1,012
1,220
Intangible assets
13
6,497
9,131
Interest in joint venture
14
1,993
1,966
9,502
12,317
4,771
3,893
Corporation tax receivable
755
392
Cash at bank and in hand
6,194
5,406
1,760
-
13,480
9,691
Non-current assets
Total non-current assets
Current assets
Trade and other receivables: due within one
year
Assets in disposal groups classified as held
for sale
15
5
Total current assets
Current liabilities
Trade and other payables: due within one
year
16
(7,609)
(8,136)
Loans and borrowings
18
(2,308)
-
Liabilities in disposal groups classified as
held for sale
5
(377)
-
(10,294)
(8,136)
(1,375)
Total current liabilities
Non-current liabilities
Trade and other payables: due after one year
17
(1,169)
Loans and borrowings
18
(5,343)
-
-
(209)
Total non-current liabilities
(6,512)
(1,584)
Net assets
6,176
12,288
78
78
56,212
56,212
2,116
2,078
(52,230)
(46,080)
6,176
12,288
Deferred tax liabilities
Capital and reserves
Called up share capital
Share premium account
Other reserves
Profit and loss account
Total equity
The notes on pages 16 to 29 form part of these interim condensed consolidated
financial statements. The interim condensed financial statements were approved
and authorised for issue by the Board and were signed on its behalf by:
John Stier, Chairman
30 August 2023
Page | 12
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Interim Condensed Consolidated Statement of Changes in
Equity
For the six months ended 30 June 2023
Called
up share
capital
Unaudited
£’000
78
Share
premium
account
Unaudited
£’000
56,212
Comprehensive
loss for the period
-
Total
comprehensive
loss for the period
Other
reserves
Total
equity
Unaudited
£’000
2,078
Profit and
Loss
Account
Unaudited
£’000
(46,080)
Unaudited
£’000
12,288
-
-
(6,150)
(6,150)
-
-
-
(6,150)
(6,150)
Share based
payments
-
-
16
-
16
Foreign exchange
movements
-
-
22
-
22
78
56,212
2,116
(52,230)
6,176
At 1 January 2023
At 30 June
2023
Page | 13
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Interim Condensed Consolidated Statement of Changes in
Equity
For the six months ended 30 June 2022
Called
up share
capital
Unaudited
£’000
72
Share
premium
account
Unaudited
£’000
50,418
Comprehensive
loss for the period
-
Total
comprehensive
loss for the period
Other
reserves
Total
equity
Unaudited
£’000
3,287
Profit and
Loss
Account
Unaudited
£’000
(24,047)
Unaudited
£’000
29,460
-
-
(11,610)
(11,610)
-
-
-
(11,610)
(11,610)
Shares issued
during the period*
6
6,064
-
-
6,070
Share based
payments
-
-
185
-
186
(35,657)
24,084
At 1 January 2022
Foreign exchange
movements
At 30 June
2022
(22)
78
56,212
3,451
*Shares issued during the period relate to a capital raising and security purchase
plan exercise completed in March 2022.
The notes on pages 16 to 29 form part of these interim condensed consolidated
financial statements.
Page | 14
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Interim Condensed Consolidated Statement of Cash Flows
Period ended
30 June 2023
Unaudited
£’000
Period ended
30 June 2022
Unaudited
£’000
18,356
(23,082)
7
(1)
196
(4,524)
16,568
(25,905)
1
(1)
267
(9,070)
(128)
(78)
(1,570)
(1,698)
(1,515)
(1,593)
-
(339)
7,500
(415)
7,085
6,409
(92)
5,978
863
(4,685)
Cash and cash equivalents at
beginning of period
Effect of movement in exchange rates
on cash held
5,406
17,068
(27)
17
Cash and cash equivalents at the end
of period
Included in cash and cash equivalents
per the balance sheet
Included in the assets of the disposal
group
6,242
12,400
6,194
12,400
48
-
Cash flows from Operating Activities
Receipts from customers
Payments to suppliers and employees
Finance income received
Finance cost paid
Government grants and tax incentives
Total Cash flows from Operating
Activities
Cash flows from Investing Activities
Payment for property, plant and
equipment
Purchase of intangible fixed assets
Total Cash flows from Investing
Activities
Cash flows from Financing Activities
Payments to suppliers in relation to
equity issue
Proceeds from equity issue
Proceeds from debt
Repayment of loans
Total Cash flows from Financing
Activities
Net Cash flows
The notes on pages 16 to 29 form part of these interim condensed consolidated
financial statements.
Page | 15
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Notes to the Interim Condensed Financial Statements
For the six month period ended 30 June 2023
1.
Corporate information
Doctor Care Anywhere Group PLC ('the Company') and its subsidiary undertakings
(together referred to as the 'Group') are engaged in digital healthcare service and
development.
Doctor Care Anywhere Group PLC is a public company limited by shares and
registered in England and Wales, registered number 08915336. Its registered office
is located at 13-15 Bouverie Street, 2nd Floor, London, England, EC4Y 8DP. It is listed
on the Australian Securities Exchange (ASX:DOC).
2.
Significant accounting policies
2.1.
Basis of preparation
The unaudited interim condensed consolidated financial statements cover Doctor
Care Anywhere Group PLC and the entities it controlled at the end of, or during,
the half year ended 30 June 2023 (referred to as the ‘Group’), and have been
prepared in accordance with IAS 34, Interim Financial Reporting. The interim
condensed consolidated financial statements do not include all the information
and disclosures required in the annual financial statements, and should be read in
conjunction with the Group’s annual consolidated financial statements prepared
in accordance with UK-adopted international accounting standards.
2.2.
Going concern
These financial statements have been prepared on a going concern basis, which
assumes that the Group will continue to be able to meet its liabilities as they fall
due for the foreseeable future, which is defined as a period of not less than twelve
months from the signing of these accounts.
The Company has prepared a cash flow forecast through to August 2024 on a
going concern basis, and the directors have considered this forecast and a range
of sensitivities carefully. Provided that the Group achieves its forecast it will
continue to be able to meet its liabilities as they fall due. For this reason, the
Company continues to adopt the going concern basis of accounting in preparing
these consolidated financial statements.
Page | 16
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
2.3.
Estimates and Judgements
The preparation of the interim financial statements requires management to make
judgements, estimates and assumptions that affect the application of policies and
reported amounts of assets and liabilities, income and expenses. These estimates,
judgements and assumptions are based on historical experience and other factors
that are believed to be reasonable under the circumstances. Actual results may
differ from these estimates. The critical accounting judgements and the major
sources of estimation uncertainty were the same as those described in the
previous annual financial statements for the year ended 31 December 2022. Details
of the estimates and judgements are included on page 68 of the 2022 Annual
Report.
3.
Revenue
Utilisation
Subscription
Other
Total revenue
Period ended
30 June 2023
Unaudited
£’000
17,870
1,281
3
19,154
Period ended
30 June 2022
Unaudited
£’000
14,258
1,129
3
15,390
Revenue streams are analysed between Utilisation, Subscription and Other
services as follows:
Utilisation revenue
UK & Republic of Ireland: Individually purchased consultations: revenue is
recognised at a point in time, when the one distinct performance obligation, the
consultation, is complete.
Australia: Revenue is recognised at a point in time, when the one distinct
performance obligation, the consultation, is complete. This revenue is recognised
net of clinician costs.
Subscription revenue
Monthly or Annual service subscription: there is one distinct performance
obligation, being the provision of virtual healthcare services. Revenue from virtual
healthcare services is recognised in the accounting period in which the services
are rendered. The contracts are satisfied monthly over the contract term. Revenue
is recognised over time, on a systematic basis over the period of the contract, as
this represents the pattern of delivery of the performance obligation to customers.
Page | 17
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
Other revenue
Minimum number of purchased consultations: some customers
purchase consultations as a bundle for a fixed amount which entitles
them to a minimum number of consultations per period. At the end of
the period and if the actual number of consultations is less than the
minimum number in the bundle, the revenue in respect of the unutilised
days is recognised in full.
Technology platform licensing: revenue is deferred and recognised
evenly over time, over the period for which the licence is granted.
A contract asset is recognised for revenue where the performance obligation
(being the provision of utilisation and subscription services) has been completed,
but payment remains conditional on acceptance by the customer. Once invoiced,
the amount recognised as contract assets is reclassified to trade receivables.
A contract liability is recognised if a payment is received or a payment is due
(whichever is earlier) from a customer before the Group transfers the related goods
or services or for instances where the customer is invoiced in advance. Contract
liabilities are recognised as revenue when the Group performs under the contract
(i.e., transfers control of the related goods or services to the customer). Contract
liabilities arise from annual service subscriptions and technology platform
licensing.
Page | 18
DocuSign Envelope ID: D8EA69E7-2D65-489C-970D-0F51613BE924
Doctor Care Anywhere
Half Year Report
4.
Segmental reporting
The Group provides virtu
Share your feedback
Discover